Drugs / Influenza Hemagglutinin mRNA vaccine
Influenza Hemagglutinin mRNA vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06118151 | Apr 2022 → Feb 2023 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Influenza Hemagglutinin mRNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06118151 ↗ |
| Modality | Messenger RNA (mRNA) | “messenger ribonucleic acid (mRNA) vaccine encoding influenza hemagglutinin” NCT06118151 ↗ |
| Route | Intramuscular | “single intramuscular (IM) injection” NCT06118151 ↗ |